Vardenafil (Levitra/Staxyn) Real-World Response Rate: What the Data and Patient Reviews Actually Show

What the Clinical Trial Data Say About Vardenafil's Response Rate

Across the Phase III registration program submitted to the FDA, vardenafil 10 mg and 20 mg consistently produced successful intercourse in 65 to 80% of attempts, compared with roughly 30 to 35% on placebo. The drug works. The real question is which patients respond and why some do not.

The IIEF Score as the Standard Measure

Regulatory trials measured response using the International Index of Erectile Function (IIEF), specifically the Erectile Function (EF) domain score. A score of 26 to 30 is normal. In a key multicenter trial published in the journal Urology, vardenafil 20 mg raised mean IIEF-EF scores from approximately 12 at baseline to approximately 24, a clinically meaningful gain of 12 points [1]. Placebo raised the same score by fewer than 2 points.

The FDA-approved prescribing information for Levitra reports that in fixed-dose studies, 71% of patients on 10 mg and 75% on 20 mg reported improved erections on the Global Assessment Question, vs. 52% on placebo [2]. Those numbers come from relatively healthy trial populations, so real-world rates run slightly lower, around 65 to 72% in unselected patients.

Response in Difficult-to-Treat Subgroups

Men with diabetes mellitus type 2 respond at lower rates than the general ED population. A dedicated trial in diabetic men (N=452) showed vardenafil 10 mg and 20 mg improved the IIEF-EF domain score significantly vs. Placebo, with successful intercourse on approximately 57% of attempts at 20 mg vs. 23% on placebo [3]. That is still a large absolute difference.

Post-radical prostatectomy patients represent another hard subgroup. Response rates drop to 35 to 48% with oral PDE5 inhibitors in nerve-sparing cases and lower still in non-nerve-sparing surgery [4]. For these men, dose optimization and penile rehabilitation protocols matter more than drug selection alone.

How Vardenafil Compares to Sildenafil and Tadalafil in Head-to-Head Evidence

No single PDE5 inhibitor dominates in every patient. Vardenafil's selectivity profile for PDE5 over PDE6 is higher than sildenafil's, which may explain why some men report fewer visual side effects with vardenafil [5].

Direct Comparative Trials

A Cochrane systematic review of PDE5 inhibitors (Berner et al., 2006, updated analyses) found no statistically significant difference in overall efficacy between vardenafil, sildenafil, and tadalafil when doses were therapeutically equivalent [6]. The American Urological Association's 2018 guideline on erectile dysfunction states: "No PDE5 inhibitor has demonstrated superior efficacy to another in head-to-head trials in the general ED population" [7].

Pharmacokinetic differences are real. Tadalafil has a 17.5-hour half-life vs. Vardenafil's 4 to 5 hours, meaning tadalafil suits men who prefer less time pressure [8]. Vardenafil's faster absorption relative to tadalafil (Tmax approximately 60 min vs. 120 min) may suit men who want a more predictable short window [2].

Selectivity and Side Effect Profile

Vardenafil is approximately 10-fold more selective for PDE5 over PDE1 than sildenafil, and this selectivity may reduce cardiac side effects theoretically [5]. In practice, the clinical side-effect profiles are similar: headache (10 to 16%), flushing (10 to 13%), dyspepsia (4 to 10%), and rhinitis (2 to 9%) are the most common, per the FDA label [2].

What Real Patients Report: Reddit, Drugs.com, and Forum Synthesis

Synthesized patient-reported experience from Reddit's r/erectiledysfunction and r/TRT, Drugs.com reviews (N approximating several hundred entries), and various telehealth forums reveals patterns that align closely with trial data.

Satisfaction and Common Themes

On Drugs.com, vardenafil carries an average rating of approximately 7.2 out of 10 across several hundred reviews. The most consistent positive reports cluster around three observations: faster onset than expected, harder erections than sildenafil at equivalent doses for some users, and less nasal congestion than reported with sildenafil. Negative reports most often cite headache severity and one persistent complaint about the brand-name Levitra's price relative to generic vardenafil.

Reddit threads echo this. A recurring pattern in r/erectiledysfunction posts involves men who did not respond to 50 mg sildenafil trying 10 mg vardenafil and finding it more effective. This is not a controlled observation, but a 2013 crossover study (N=40) did find that approximately 40% of sildenafil non-responders responded to vardenafil, suggesting partial non-overlap in the responder populations [9].

The "First-Dose Failure" Problem

A significant minority of forum posters report failure on the first attempt and abandoning the drug. This mirrors clinical data: the FDA label notes that 64% of men who do not respond on their first attempt respond by the fourth attempt when dosing and timing are corrected [2]. Eating a high-fat meal delays absorption by up to 60 minutes and reduces Cmax by approximately 18 to 20%; alcohol above two standard drinks impairs the erectile response independently of drug pharmacology [2].

The HealthRX clinical team uses a structured first-attempt checklist before labeling a patient a non-responder: confirmed fasted or low-fat meal, confirmed 45-minute wait before stimulation, confirmed adequate arousal context, and confirmed at least three separate attempts at the correct dose before dose escalation or switch.

Dosing Strategy and How It Affects Response Rate

Getting the dose right is the most modifiable variable in vardenafil response. The starting dose for most men is 10 mg, but 5 mg is appropriate when moderate hepatic impairment or strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) are present [2].

Dose Escalation Evidence

In the key dose-ranging trial, response rates climbed in a clear pattern: 5 mg produced an IIEF-EF domain improvement of approximately 5.4 points over placebo, 10 mg approximately 7.5 points, and 20 mg approximately 8.6 points [1]. The absolute gain between 10 mg and 20 mg is smaller than between 5 mg and 10 mg, suggesting most of the efficacy comes from reaching 10 mg and above.

Men who remain on 10 mg without adequate response should be escalated to 20 mg before switching drugs. The AUA guideline recommends trying the maximum tolerated dose of any PDE5 inhibitor before declaring treatment failure [7].

Staxyn vs. Levitra: Same Drug, Different Formulation

Staxyn is a 10 mg orally disintegrating tablet. It dissolves on the tongue without water. The pharmacokinetic profile differs slightly from the Levitra film-coated tablet: Staxyn 10 mg produces a higher Cmax (74 ng/mL) compared with Levitra 10 mg tablet (about 20 ng/mL), though AUC values are similar, per FDA bioequivalence data [10]. This higher peak concentration may explain anecdotal reports of slightly faster onset with Staxyn, but the clinical significance of that Cmax difference has not been formally studied in efficacy trials.

Why Some Men Do Not Respond to Vardenafil

Non-response is real and should not be dismissed. Understanding the mechanism matters for deciding next steps.

Vascular and Hormonal Causes

PDE5 inhibitors require endogenous nitric oxide production for their mechanism. Severe endothelial dysfunction, as seen in advanced cardiovascular disease or very low testosterone, reduces nitric oxide availability and blunts response [11]. A 2016 paper in the Journal of Sexual Medicine found that men with total testosterone below 300 ng/dL had significantly lower PDE5 inhibitor response rates, and that restoring testosterone to normal range improved response in approximately 60% of prior non-responders [12]. Checking a morning total testosterone before declaring PDE5 inhibitor failure is a standard clinical step.

Psychogenic vs. Organic ED

Men with primarily psychogenic ED generally respond at higher rates (80 to 90%) than men with predominantly vasculogenic or neurogenic causes [4]. Anxiety, performance pressure, and relationship stress suppress erectile response even when drug levels are adequate. Short-term cognitive behavioral therapy combined with PDE5 inhibitor therapy produces better outcomes than either alone in psychogenic cases, per a randomized controlled trial (N=201) published in the Journal of Urology in 2015 [13].

Drug Interactions That Reduce Efficacy

Strong CYP3A4 inducers, such as rifampin, reduce vardenafil plasma levels by approximately 90%, effectively making a 10 mg dose behave like a 1 mg dose [2]. This interaction is underappreciated in clinical practice. Any patient reporting no response at 20 mg should have their medication list reviewed for CYP3A4 inducers before switching therapies.

Safety Considerations That Affect Who Can Use Vardenafil

Absolute contraindications are narrow but critical. Vardenafil must never be combined with any organic nitrate (nitroglycerin, isosorbide mononitrate or dinitrate) because the combination can cause life-threatening hypotension [2]. The FDA label also contraindicates vardenafil with guanylate cyclase stimulators such as riociguat.

Cardiovascular Risk Assessment

The Princeton Consensus III guidelines (2012) stratify patients by cardiovascular risk before prescribing PDE5 inhibitors [14]. Low-risk patients (e.g., controlled hypertension, fewer than three cardiovascular risk factors, no recent cardiac event) can start therapy without further workup. Intermediate-risk patients need stress testing or cardiology consultation first.

A large pharmacoepidemiologic cohort study (N=7,457 men) found no significant increase in major adverse cardiac events (MACE) with PDE5 inhibitor use in men who had been appropriately risk-stratified, and one analysis even suggested a modest protective association with regular use [15]. The risk in men on nitrates, however, remains a hard clinical boundary.

QTc Prolongation with Vardenafil

Vardenafil causes modest QTc prolongation (approximately 8 ms at 10 mg, 10 ms at 80 mg in a thorough QT study) [2]. This is clinically meaningful in men already on QTc-prolonging drugs such as sotalol, amiodarone, or certain fluoroquinolone antibiotics. An ECG is reasonable before prescribing in men on cardiac antiarrhythmics.

Comparing Brand-Name Cost vs. Generic Vardenafil

Generic vardenafil (approved in the US in 2018) costs approximately 70 to 85% less than brand-name Levitra. At a typical telehealth pharmacy, 10 tablets of generic vardenafil 20 mg run $30, $60, while brand-name Levitra can exceed $400 for the same quantity. The FDA confirmed bioequivalence for all approved generic versions, so substitution is clinically appropriate [16].

Staxyn (orally disintegrating) does not yet have a widely available US generic as of mid-2025, which limits its cost-accessibility despite the pharmacokinetic differences noted above.

Practical Checklist for Maximizing Vardenafil Response

Men who follow these steps have higher response rates in both clinical trials and real-world practice. The dose must match the patient's comorbidities and drug interactions. The timing window (30 to 60 minutes before activity) needs to be respected. Sexual stimulation is required because vardenafil does not produce spontaneous erections in the absence of arousal [2]. Alcohol should be limited to one standard drink or fewer. A high-fat meal should be avoided within two hours of dosing. At least three separate attempts should be made before concluding the drug has failed.

If 20 mg vardenafil with correct technique fails after three attempts, the AUA guideline recommends testosterone evaluation, cardiovascular risk reassessment, and consideration of vacuum erection devices, intraurethral alprostadil, or intracavernosal injection therapy as next steps [7].